Goldman Sachs's new immunotherapy pioneer Attovia (ATTO.US) sprinted to NASDAQ: raised up to US$2125 million, becoming the latest footnote on the biotech IPO boom

Zhitong Finance App learned that in the context of biotech IPOs crushing the AI sector with an average return of 55% and becoming the biggest winner in US stocks in 2026, another clinical-stage biopharmaceutical company has joined the listing boom. Attovia Therapeutics Inc. (ATTO.US) — an early-stage drug developer focused on immune-mediated diseases and endorsed by top institutions such as Goldman Sachs — submitted its latest prospectus to the US Securities and Exchange Commission (SEC) on Wednesday. It plans to issue 12.5 million shares at a price of $15 to $17 per share, with a maximum capital of around $212.5 million. Based on the upper limit of the distribution range, the San Carlos (San Carlos), California-based biotech company will have a market capitalization of close to $655 million.

Distribution Overview: From $100 million to $2125 million, demand-driven scaling

When Attovia first submitted an IPO application on July 14, it planned to raise around $100 million. In just two weeks, strong demand from investors drove the company to significantly expand its offering — the final pricing range was set at $15 to $17 per share, and 12.5 million shares were issued. At the midpoint of the range, Attovia's fully diluted market capitalization is approximately US$649 million.

According to management's presentation, the IPO is expected to be priced on August 4 (next Tuesday). Shares will be traded on the NASDAQ Global Market under the ticker symbol “ATTO.” Morgan Stanley, Leerink Partners, Citigroup, and Royal Bank of Canada acted as joint bookkeepers for this offering.

Capital map: Goldman Sachs leads the investment, and $255.8 million ammunition is in place

As a clinical-stage biotech company, Attovia has received strong financial support from top institutional investors. As of March 31, 2026, the company's cumulative financing reached US$255.8 million. The lineup of major shareholders is luxurious: Goldman Sachs Group affiliates, Deep Track Capital, Frazier Life Sciences, and Venbio.

Deep Track Capital, Frazier Life Sciences, and Venbio each hold at least 5% of the company's shares, according to SEC filings. In April 2025, Attovia completed a $90 million Series C round led by Deep Track Capital. Participants include new investors such as Vida Ventures, Sanofi Ventures (Sanofi Ventures), Mirae Asset Life Science, as well as Frazier Sciences Life, VenBio, Goldman Sachs (Goldman Sachs) Continued support from existing investors such as Alternatives).

Technology platform and pipeline: ATTOBODY nanoantibody platform's tertiary rocket

Established in 2022, Attovia's core technology “ATTOBODY” platform is a biotechnology platform based on biparatopic nanoantibodies (biparatopic nanobody), obtained an exclusive license from Alamar Biosciences (ALMR.US). The platform enables the development of multi-specific antibody therapies targeting complex immune targets.

The company currently has three drugs under development, forming a clear stepped pipeline layout:

Among them, ATTO-1310 is the company's core asset. The drug has completed phase I clinical trial administration for healthy volunteers and patients with chronic pruritus and atopic dermatitis. As a bispecific antibody targeting IL-13 and IL-31, ATTO-2306 is expected to achieve more comprehensive efficacy coverage in the field of atopic dermatitis. As a tri-specific antibody, ATTO-1091 also targets the three popular immune targets of TL1A, IL-23, and integrin α4β7, pointing to the huge inflammatory bowel disease market.

Alamar Biosciences' “Incubation Legend”: Parent shares have risen 43%

The birth of Attovia itself is a successful example of capital operation. In 2023, Alamar Biosciences, a medical device company focused on proteomics and disease detection, spun off Attovia into an independent company to focus on its core business. Alamar is still an important shareholder of Attovia. In April 2026, Alamar Biosciences completed an IPO, raising US$219.9 million. Since its listing, its stock price has increased by a cumulative total of 43%. The parent company's successful listing and outstanding performance provided a strong endorsement and valuation reference for Attovia's IPO.

Market background: the “golden window” of biotech IPOs

It is no accident that Attovia chose to go public at this time — 2026 is becoming the “big year” for biotech IPOs.

The return rate overwhelms AI: According to Bloomberg data, as of July 17, the weighted average return on IPOs of US biotech and pharmaceutical companies was as high as 55%, while the average return on the overall IPO market after excluding SPAC was a loss of 4.4%. The biotech sector outperformed the market by nearly 60 percentage points and became the biggest winner in the 2026 US stock IPO market.

Individual stock performance was astonishing: Veradermics Inc., which treats hair loss, soared 534% since its listing in February, making it the best-performing IPO in the US in 2026; Hemab Therapeutics Holdings Inc., which focuses on blood diseases, has risen 149% since listing in May.

Strong momentum in the sector: As of mid-July, the number of biotech IPOs in 2026 had surpassed the total of last year, and the total amount raised exceeded 5 billion US dollars, about three times that of the same period last year. Jack Bannister, senior managing director of equity capital markets at Leerink Partners, described the current environment as “the healthiest biotech IPO market in a long time.” At least six other biotech companies have applied for IPOs in July and are expected to complete pricing before the end of summer.

The strong performance of the biotech sector was due to multiple factors: the Nasdaq Biotech Index rose 13% during the year, a more stable regulatory environment, breakthrough progress in clinical trial data, and the restart of mergers and acquisitions by major pharmaceutical companies.